Incidence of side effects using carbon dioxide-oxygen foam for chemical ablation of superficial veins of the lower extremity

Eur J Vasc Endovasc Surg. 2010 Sep;40(3):407-13. doi: 10.1016/j.ejvs.2010.04.018. Epub 2010 May 23.

Abstract

Objectives: To determine the incidence of side effects following treatment of varicose veins with carbon dioxide-oxygen (CO(2)/O(2)) foam sclerotherapy, and to compare results with historical controls using CO(2)- or air-based foams.

Design: Cohort study with prospective data collection, private clinic setting.

Patients: The patient population consisted of one hundred patients, 95% women, age 52 SD 13 years-old, CEAP class C(2)EpAsPr.

Methods: Patients underwent ultrasound-guided foam sclerotherapy following thermal ablation of saphenous trunks; 1-3% polidocanol and 70%CO(2)-30%O(2) gas were mixed in a 1:4 proportion. Volume injected averaged 22 SD 11 (range: 2-46) mL. Vital signs were monitored for 1 h; side effects were recorded up to 24 h post treatment. Incidence of side effects was compared to CO(2)- and air-based foam data.

Results: Heart rate decreased from 73 SD 11 at the start to 68 SD 9 bpm (p < 0.001, paired t-test) following the procedure. Systolic and diastolic pressures, 127/75 SD 18/14 mmHg, respiratory rate, 15 SD 4 rpm and pO(2), 98 SD 2%, did not change significantly. Itching (7) or leg pain (24) reporting was similar to that for air-based foam (p = NS). Lack of reported chest tightness and/or dry cough was superior to our previous data with CO(2) or air foam (p < 0.05). Reporting of dizziness (1) was less than that for air-based foam (p = 0.002). The incidence of visual disturbance (2%), was comparable with that for CO(2) (3%) or air (8%) foam, but too few cases were available for meaningful statistical analysis.

Conclusions: Foam sclerotherapy using CO(2)/O(2) foam was well tolerated by patients and resulted in fewer side effects than similar treatment using air foams.

MeSH terms

  • Adult
  • Aged
  • Carbon Dioxide / adverse effects
  • Carbon Dioxide / therapeutic use*
  • Female
  • Humans
  • Lower Extremity / blood supply*
  • Male
  • Middle Aged
  • Oxygen / adverse effects
  • Oxygen / therapeutic use*
  • Polidocanol
  • Polyethylene Glycols / therapeutic use*
  • Prospective Studies
  • Sclerosing Solutions / adverse effects
  • Sclerosing Solutions / therapeutic use*
  • Sclerotherapy / adverse effects
  • Sclerotherapy / methods*
  • Time Factors
  • Treatment Outcome
  • Ultrasonography, Interventional
  • Varicose Veins / diagnostic imaging
  • Varicose Veins / therapy*

Substances

  • Sclerosing Solutions
  • Polidocanol
  • Carbon Dioxide
  • Polyethylene Glycols
  • Oxygen